Prohost Letter #388
TOPICS -
1. AN INDISPENSABLE SHORT INTRODUCTION
2. GENE EDITING
3. GENE THERAPY
4. CANCER IMMUNOTHERAPY

1. GENE EDITING
Exon Skipping: Biomarin (BMRN); Sarepta (SRPT);
These firms are waiting FDA approvals for Duchenne Muscular Dystrophy (DMD)

Gene Editing Technology Competitors:
Cellectis S.A. (CLLS); CRISPR; PTC Therapeutics (PTCT)

Firms Using Different Approaches For DMD Treatment (see Below)
Zink Finger Tech: Sangamo (SGMO);
RNAi technology: Alnylam (ALNY); Isis (ISIS); Abus (ABUS . . .